mAbxience

What mAbxience does

mAbxience is a vertically integrated biopharmaceutical company that develops, manufactures, and commercializes biosimilars and provides contract development and manufacturing (CDMO) services to global biopharmaceutical partners. Founded in 2009 and operating as a subsidiary of Fresenius Kabi, the company runs two integrated business lines: an in-house biosimilar development program with current commercial focus on denosumab-based products (Boncresa and Oziltus FDA-approved in the US for osteoporosis and bone cancer indications; Izamby and Denbrayce marketed in 15+ European countries) and an independent CDMO platform offering end-to-end manufacturing services from research batches to commercial scale.

The company's technical platform is anchored in proprietary bioprocess development and manufacturing capabilities, augmented by recent technology partnerships: an AI-driven biomanufacturing optimization initiative with HP Inc. using digital twin technology (announced December 2025) and Genedata Bioprocess, a SaaS-based bioprocess data management platform (implementation announced March 2026). mAbxience has over a decade of experience in the development and commercialization of biopharmaceuticals and holds regulatory clearances across multiple jurisdictions (FDA in the US, CE Mark in Europe).

mAbxience's business model operates through two distinct revenue mechanics. The CDMO arm generates professional services revenue from biopharmaceutical clients requiring contract development and manufacturing. The biosimilar arm operates on a licensing/royalty model where mAbxience handles development and manufacturing while strategic partners — Amneal Pharmaceuticals for the US market (exclusive commercialization rights) and Abbott for emerging markets — commercialize products in their territories. The company serves healthcare providers and patients indirectly through these commercialization partners, with end markets spanning the US, 15+ European countries, and emerging markets. Pricing and contract terms are not publicly disclosed.

Name

mAbxience

Legal name

MABXIENCE HOLDING SL

Website

https://mabxience.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

mAbxience is a Fresenius Kabi subsidiary that develops and manufactures biosimilars (notably denosumab products for osteoporosis and bone cancer) and provides CDMO services to global biopharmaceutical partners across the US, Europe, and emerging markets.

Ownership category

akta.pro rank

Product category

Biosimilars and Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Biosimilar development
• Biopharmaceutical manufacturing
• CDMO services
• Biologics contract development
• Denosumab biosimilars

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations

Revenue model

1. CDMO Services: Contract development and manufacturing organization services providing integrated biopharmaceutical solutions from research batches to commercial batches, both large and small scale.
2. Biosimilar Development and Commercialization: Development and manufacturing of biosimilar products through strategic partnerships, where mAbxience handles development and manufacturing while partners commercialize products in their territories.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

mAbxience is a vertically integrated biopharmaceutical company that develops and manufactures biosimilars (notably FDA-approved denosumab biosimilars Boncresa and Oziltus referencing Prolia and XGEVA) and operates an independent CDMO platform providing end-to-end development and manufacturing services from research batches to commercial batches. The company commercializes its biosimilars through strategic partners such as Amneal Pharmaceuticals (US) and Abbott (emerging markets) while offering integrated biopharmaceutical services globally.

Product overview

mAbxience is a vertically integrated biopharmaceuticals company specializing in biosimilars and CDMO services. The company operates two core platforms: Biosimilar Development (including Boncresa, Oziltus, Izamby, and Denbrayce denosumab biosimilars) and an independent CDMO platform providing end-to-end manufacturing solutions. The biosimilar portfolio focuses on denosumab-based products for osteoporosis and bone cancer indications, while the CDMO services offer integrated manufacturing from research through commercial scale.

Differentiator

Problem solved

Functional benefit

Products and services

• Boncresa (Denosumab Biosimilar) FDA-approved denosumab biosimilar referencing Prolia, developed through partnership with Amneal Pharmaceuticals who holds exclusive US commercialization rights, for the treatment of osteoporosis and bone-related conditions.
• Oziltus (Denosumab Biosimilar) FDA-approved denosumab biosimilar referencing XGEVA, developed through partnership with Amneal Pharmaceuticals who holds exclusive US commercialization rights, for the prevention of skeletal-related events in patients with bone metastases.
• Izamby (Denosumab 60mg Biosimilar) Denosumab 60mg biosimilar approved in European markets for osteoporosis treatment, with patient information materials available in multiple EU countries including Spain, Italy, Croatia, Poland, Denmark, Hungary, Netherlands, Sweden, Romania, Austria, Germany, Norway, UK, and Finland.
• Denbrayce (Denosumab 120mg Biosimilar) Denosumab 120mg biosimilar approved in European markets for bone cancer treatment, with patient reminder cards available in multiple EU countries.
• CDMO Services Independent Contract Development and Manufacturing Organization (CDMO) platform providing end-to-end integrated biopharmaceutical solutions from research batches to commercial batches, both large and small scale, with over a decade of experience in biopharmaceutical development and commercialization. Serves pharmaceutical companies and biotech firms requiring contract manufacturing services for biologics and biosimilars.

Quantifiable outcome

• FDA approval of two denosumab biosimilars (Boncresa and Oziltus) expanding access to affordable biologic medicines in the United States.
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• GenedatasupportingTechnology or Integration · 10 March 2026mAbxience selected Genedata Bioprocess to implement an automated, SaaS-based platform for bioprocess data management across its biopharmaceutical operations. This strategic move aims to improve process efficiency, data integrity, and support future AI-driven process optimization.
• Amneal PharmaceuticalscoreStrategic or Co-development Partner · 22 December 2025mAbxience and Amneal announced FDA approval of two denosumab biosimilars (Boncresa referencing Prolia and Oziltus referencing XGEVA). mAbxience handles development and manufacturing while Amneal holds exclusive US commercialization rights. This partnership expanded Amneal's biosimilar portfolio to five commercial products.
• HP Inc.coreTechnology or Integration · 3 December 2025mAbxience and HP Inc. announced a collaboration to develop an AI solution for optimizing biologic manufacturing processes, including creating a digital twin to improve efficiency and predictability. The project aims to enhance biologics development, operational efficiency, and resource utilization with potential for global replication.
• AbbottcoreStrategic or Co-development Partner · 19 November 2025Abbott expanded a biosimilar collaboration with mAbxience Holdings S.L. for emerging markets. This collaboration supports Abbott's affordable medicines strategy and expands access to biosimilar treatments in developing regions.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Samsung Bioepis: Biosimilars-focused subsidiary of Samsung Biologics developing and commercializing monoclonal antibody biosimilars (e.g., denosumab, ranibizumab, bevacizumab). Directly comparable to mAbxience as a vertically integrated mAb biosimilar developer with global commercialization partnerships.
• Celltrion: Korean biopharmaceutical company that develops, manufactures, and commercializes biosimilars including infliximab, trastuzumab, rituximab, and denosumab biosimilars. Highly comparable in product category (mAb biosimilars), business model (in-house development plus partnered commercialization), and customer base.
• Alvotech: Iceland-based biosimilar developer with a portfolio including denosumab biosimilars (referencing Prolia/XGEVA). Direct competitor to mAbxience in the same mAb biosimilar molecules, with comparable vertically integrated development and manufacturing model.
• Biocon Biologics: India-headquartered biosimilar business of Biocon Limited, developing and commercializing biosimilars such as trastuzumab, bevacizumab, insulin glargine, and denosumab. Comparable product portfolio, manufacturing scale, and emerging-market commercialization footprint.
• Polpharma Biologics: European biosimilar developer and manufacturer with a pipeline of biosimilars including ranibizumab, natalizumab, and others. Comparable vertically integrated biosimilar development and CDMO operations, with geographic overlap in European markets.

Broad incumbents

• Samsung Biologics: Larger Korean contract development and manufacturing organization (CDMO) for biologics with significant manufacturing capacity and broader client base than mAbxience. Comparable in CDMO capabilities for biopharmaceuticals and in deploying AI/data-driven manufacturing optimization.
• Boehringer Ingelheim BioXcellence: CDMO arm of Boehringer Ingelheim providing contract development and manufacturing services for biopharmaceuticals and biosimilars. Comparable on the CDMO side, with overlapping capabilities in biologics manufacturing and biosimilar process development.
• Amgen: Originator of Prolia/XGEVA (denosumab) and other biologics, also active in biosimilars. Comparable because mAbxience's flagship products directly reference Amgen brands, and Amgen sets the competitive dynamic (defensive pricing, lifecycle management) that will shape mAbxience's US economics.

Others

• Fresenius Kabi: Parent company of mAbxience, a global healthcare company providing pharmaceutical and medical device products. Included as the parent rather than a direct competitor; relevant for understanding ownership structure, capital allocation, and strategic priorities constraining or supporting mAbxience.
• Amneal Pharmaceuticals: Exclusive US commercialization partner for mAbxience's biosimilars and a biosimilar developer in its own right. Comparable as a participant in the same biosimilar value chain, and material to mAbxience's US commercial trajectory though it does not directly compete on manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Mabxience
• LinkedInlinkedin.com/company/2733245

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mAbxience